

2

3

4 **Abstract**

5 Chalcones are a class of natural products reported with a wide range of biological activities.
6 Among them antibacterial is much promising and many potent chalcones have been emerged
7 as useful antibacterial agents. In view of this, we synthesized 15 chalcones (**3a-3o**) containing
8 both hydroxyl and chlorine substituents and studied them by using spectroscopic methods.
9 The compounds were tested for antibacterial efficacy against *Staphylococcus aureus*, *Bacillus*
10 *subtilis*, *Escherichia coli*, and *Proteus vulgaris*, among other harmful microorganisms. The
11 compounds have moderate to high antibacterial activity, among them heteroaromatic ring
12 containing compounds (**3m, 3n, and 3o**) elicited higher activity than the standard drug
13 benzyl penicillin. The compound **3m** having the pyridinyl compound displayed the maximum
14 activity against *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli*, and *Proteus*
15 *vulgaris*, with zone of inhibition (in mm) values of 27.52 ± 0.16 , 28.85 ± 0.11 , 22.05 ± 0.16 , and
16 23.18 ± 0.17 , respectively. The synthesized compounds could be used as lead molecules in the
17 development of novel antibacterial medicines.


18 **Key Words:** Chalcone; Spectroscopic methods; Antibacterial activity; Heteroaromatic;
19 Benzyl penicillin.

20 **Introduction**

21 Natural products contain a diverse range of secondary metabolites, including flavonoids and
22 isoflavonoids, which have been linked to a significant number of medications used in the
23 treatment of different diseases including microbial infections and cancer [1]. Chalcone is a
24 chemically open-chain flavonoid with two aromatic rings linked by α , β -unsaturated
25 propenone [2]. Plants with high in flavonoid derivatives should be included in our diet on a
26 regular basis as such practices will have considerable health benefits. A part from that,
27 chalcones are important in the treatment of a variety of disorders [3]. Chalcone's chemical
28 template has the ability to participate in a variety of metabolic reactions and physiological
29 processes that provide good impact on our health [4-6]. Chalcones possess different activities
30 like antibacterial [7-10], antifungal [11-13], anticancer [14-16], anti-inflammatory [17-19],
31 antioxidant [20-22], cytotoxic [23-24], antimalarial [25-27] etc.

32 Furthermore, the structures of these molecules are straightforward, and they can be easily
33 produced in the laboratory. In response to these two characteristics of chalcones, academic
34 and industry researchers have been working hard to develop, manufacture and test chalcones
35 with a variety of substituents and changed versions in order to produce novel compounds
36 with good biological functions. Based on the foregoing, we present the synthesis and
37 antibacterial evaluation of 15 chalcone derivatives (**3a-3o**) containing chlorine and hydroxyl
38 substituents on one phenyl ring portion (ring-A) and another phenyl ring portion (ring-B)
39 replaced with either a bioisosteric heteroaryl ring or a phenyl ring containing electron

40 withdrawing or releasing substituents in order to assess the influence of the chalcone on
41 antibacterial activity (Figure 1).



44 Figure 1. General structure of chalcone and the structure of target chalcones (**3a-3o**)

45 **Materials and Methods**

46 **General**

47 All the chemicals including the ketone and aromatic aldehydes, reagents and solutions used
48 in the study were procured from Sigma Aldrich and S.D. Fine Chemicals. The melting points
49 of all 15 target compounds were determined using a Boetius melting point apparatus, and the
50 ¹H NMR and ¹³C-NMR spectra were acquired using Bruker Avance 400 NMR
51 spectrophotometers (Bruker Switzerland AG) at 400 and 100 MHz for the ¹H and ¹³C
52 nuclei, respectively, and the results were reported as chemical shifts for all 15 target
53 compounds (ppm). The FT-IR was scanned on a Bruker alpha-T (BRUKER biospin
54 International AG., Zug, Switzerland) and the wave numbers were reported in cm⁻¹. The mass
55 spectra were scanned using an Agilent LC-MS spectrometer (Agilent technologies, USA). To
56 monitor the chemical reactions and determine the purity of the compounds, a precoated silica
57 gel-G TLC (Merck) with a 20-30 percent ethyl acetate-hexane mobile phase was employed in
58 conjunction with a precoated silica gel-G TLC (Merck). A UV light was used to watch the
59 TLC plate in action.

60 **Synthetic protocol:** Equimolar concentrations of the ketone i.e., 5'-chloro-2'-hydroxy
61 acetophenone (1 mmol) and substituted aromatic aldehydes (1 mmol) were dissolved in 7.5
62 mL of ethanol. To the above mixture, 7.5 mL of 50 percent alcoholic KOH was added
63 dropwise and the reaction mixture was allowed to react for 24 h at room temperature. At the
end of the reaction (monitored by TLC), the reaction mixture was neutralized with 1:1

64 solution of hydrochloric acid and water for the precipitation of the target chalcones (**3a-3o**).

65 The chalcones formed were filtered using vacuum filtration and then washed in cold water,

66 dried, and recrystallized in either ethanol or chloroform to complete the process (Scheme 1).

67 Table 1: The physicochemical and spectral features of the compounds are reported

68 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(2''-fluorophenyl)prop-2-ene-1-one (**3a**): Yellow color solid;
69 Yield: 74%. Recrystallized from ethanol. m.p: 160 °C; **FT-IR** (KBr ν_{\max} cm^{-1}): 668 (C-Cl), 1215 (C-
70 F), 1610 (str, CH=CH, conjugated), 1717 (intense conjugated C=O band), 3344 (Ar-OH); **¹H NMR**
71 (CDCl₃ 400 MHz) δ (ppm): 7.17 (d, 1H, H _{α} , $J = 16.1$ Hz), 7.09 (d, 1H, H _{β} , $J = 16$ Hz), 7.24-7.68 (m,
72 7H, Ar-H), 11.96 (s, Ar-OH); LC-MS: m/z 276.69 (M⁺, 99.06), 278.69 (M+2, 33.02).

73 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(3''-fluorophenyl)prop-2-ene-1-one (**3b**): Yellow color solid;
74 Yield: 84%. Recrystallized from ethanol. m.p: 151 °C; **FT-IR** (KBr ν_{\max} cm^{-1}): 771 (C-Cl), 1214 (C-
75 F), 1611 (str, CH=CH, conjugated), 1717 (intense conjugated C=O band), 3344 (Ar-OH); **¹H NMR**
76 (CDCl₃ 400MHz) δ (ppm): 7.17 (d, 1H, H _{α} , $J = 16.0$ Hz), 7.10 (d, 1H, H _{β} , $J = 16$ Hz), 7.24-7.69 (m,
77 7H, Ar-H), 11.96 (s, Ar-OH); LC-MS: m/z 276.69 (M⁺, 99.06), 278.69 (M+2, 33.02).

78 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(4''-fluorophenyl)prop-2-ene-1-one (**3c**), yellow color solid,
79 yeild 85%. Recrystallized from ethanol. m.p: 160 °C; **FT-IR** (KBr ν_{\max} cm^{-1}): 771 (C-Cl), 1215 (C-
80 F), 1623 (str, CH=CH, conjugated), 1720 (intense conjugated C=O band), 3200 (Ar-OH); **¹H NMR**
81 (CDCl₃ 400MHz) δ (ppm): 7.26 (d, 1H, H _{α} , $J=16.0$ Hz), 7.52 (d, 1H, H _{β} , $J=16.0$ Hz), 7.24-7.69 (m,
82 7H, Ar-H), 11.89 (s, Ar-OH); LCMS: m/z 276.69 (M⁺, 99.08), 278.69(M+2, 33.02).

83 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(2''-chlorophenyl)prop-2-ene-1-one(**3d**): Yellow color solid,
84 Yield: 75%. Recrystallized from ethanol (Sawant and Nirwan., 2013). **FT-IR** (KBr ν_{\max} cm^{-1}): 706 (C-
85 Cl), 794 (C-Cl), 1626 (str, CH=CH, conjugated), 1721 (intense conjugated C=O band), 3349 (Ar -
86 OH); **¹H NMR** (CDCl₃ 400 MHz) δ (ppm): 7.43 (d, 1H, H _{α} , $J=16.1$ Hz), 7.92 (d, 1H, H _{β} , $J=16.3$ Hz),
87 7.04-8.93 (m, 7H, Ar-H), 12.36 (s, Ar-OH); LC-MS: m/z 293.14 (M⁺, 99.06), 295.14 (M+2,
88 33.01).(literature (28)).

89

90 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(3''-chlorophenyl)prop-2-ene-1-one (**3e**), yellow color solid,
91 yeild 80%. Recrystallized from ethanol. m.p: 161 °C; **FT-IR** (KBr ν_{\max} cm^{-1}), 699 (C-Cl), 780 (C-
92 Cl), 1622 (str, CH=CH, conjugated), 1718 (intense conjugated C=O band), 3344 (Ar -OH); **¹H NMR**
93 (CDCl₃ 400MHz) δ (ppm): 7.44 (s, Ar-OH), 7.48 (d, 1H, H _{α} , $J=16.2$ Hz), 7.98 (d, 1H, H _{β} , $J=16.0$
94 Hz), 7.08-8.98 (m, 7H, Ar H); LCMS: m/z 293.14 (M⁺, 99.02), 295.14 (M+2, 33.00).

95 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(4''-chlorophenyl)prop-2-ene-1-one (**3f**): Yellow color
96 solid, Yield: 82%. Recrystallized from ethanol. m.p: 161 °C; **FT-IR** (KBr ν_{\max} cm^{-1}): 786 (C-
97 Cl), 1667 (str, CH=CH conjugated), 1751 (intense conjugated C=O band), 3253 (Ar-OH); **¹H**
98 **NMR** (CDCl₃ 400 MHz) δ (ppm): 7.42 (d, 1H, H _{α} , $J=16.2$ Hz), 7.86 (d, 1H, H _{β} , $J=16.0$ Hz),
99 7.09-8.91 (m, 7H, Ar H), 12.31 (s, Ar-OH); LC-MS: m/z 293.14 (M⁺, 99.09), 295.14 (M+2,
100 33.04). (literature (29)).

101

102 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(2''-hydroxyphenyl)prop-2-ene-1-one (**3g**), yellow color
103 solid, yeild 80%. Recrystallized from chloroform. m.p: 200 °C; **FT-IR** (KBr ν_{\max} cm⁻¹), 795 (C-
104 Cl), 1665 (str, CH=CH conjugated), 1756 (intense conjugated C=O band), 2800 (Ar-OH), 3230 (Ar -
105 OH); ¹H NMR (CDCl₃ 400MHz) δ (ppm): 6.94 (Ar-OH), 6.97 (s, Ar-OH), 7.57 (d, 1H, H _{α} ,
106 $J=16.5$ Hz), 7.84 (d, 1H, H _{β} , $J=16.0$ Hz), 6.72-8.08 (m, 7H, Ar-H); **LC-MS**: m/z 274.70 (M⁺, 99.09),
107 276.70(M+2, 33.03);

108 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(3''-hydroxyphenyl)prop-2-ene-1-one (**3h**): Yellow color solid,
109 Yield: 75%. Recrystallized from chloroform. Mp:200°C; **FT-IR** (KBr ν_{\max} cm⁻¹): 795 (C-Cl), 1665
110 (str, CH=CH conjugated), 1756 (intense conjugated C=O band), 3255 (Ar-OH); ¹H NMR (CDCl₃ 400
111 MHz) δ (ppm): 5.41 (s, Ar-OH), 7.49 (d, 1H, H _{α} , $J = 16.2$ Hz), 7.81 (d, 1H, H _{β} , $J = 16.2$ Hz), 6.89-8.16
112 (m, 7H, Ar-H), 12.24 (s, Ar-OH); **LC-MS**: m/z 274.70 (M⁺, 99.02), 276.70 (M+2, 33.00). (literature
113 (30)).

114 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(4''-hydroxyphenyl)prop-2-ene-1-one(**3i**):Yellow color solid,
115 Yield: 70%. Recrystallized from chloroform. m.p: 200 °C; **FT-IR** (KBr ν_{\max} cm⁻¹): 799 (C-Cl), 1672
116 (str, CH=CH conjugated), 1759 (intense conjugated C=O band), 3258 (Ar-OH); ¹H NMR (CDCl₃ 400
117 MHz) δ (ppm): 5.34 (s, Ar-OH), 7.53 (d, 1H, H _{α} , $J = 16.2$ Hz), 7.86 (d, 1H, H _{β} , $J = 16.2$ Hz), 6.96-8.33
118 (m, 7H, Ar-H), 12.30 (s, Ar-OH); **LC-MS**: m/z 274.70 (M⁺, 99.07), 276.70 (M+2, 33.04). (literature
119 (31)).

120 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(2''-methoxyphenyl)prop-2-ene-1-one(**3j**):Yellow color solid,
121 Yield: 85%. Recrystallized from chloroform. **FT-IR** (KBr ν_{\max} cm⁻¹): 778 (C-Cl), 1681 (str, CH=CH
122 conjugated), 1782 (intense conjugated C=O band), 2831 (-OCH₃), 3516 (Ar -OH); ¹H NMR (CDCl₃
123 400 MHz) δ (ppm): 2.41 (Ar-OCH₃), 7.78 (d, 1H, H _{β} , $J = 16.3$ Hz), 7.89 (d, 1H, H _{α} , $J = 16.2$ Hz), 6.61-
124 8.17 (m, 7H, Ar- H), 12.39 (s, Ar-OH); **LC-MS**: m/z 288.06 (M⁺, 99.05), 290.06 (M+2, 33.04).
125 (literature (31)).

126 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(3''-methoxyphenyl)prop-2-ene-1-one (**3k**), yellow color
127 solid, yeild 80%. Recrystallized from chloroform. m.p: 150°C; **FT-IR** (KBr ν_{\max} cm⁻¹), 775 (C-
128 Cl), 1685 (str,CH=CH conjugated), 1780 (intense conjugated C=O band), 2823 (C-OCH₃), 3500
129 (Ar -OH); ¹H NMR (CDCl₃ 400MHz) δ (ppm): 6.95 (Ar-OCH₃), 7.03 (s, Ar-OH), 7.75 (d, 1H, H _{β} ,
130 $J=16.2$ Hz), 7.85 (d, 1H, H _{α} , $J=16.75$ Hz), 6.56-8.08 (m, 7H, Ar- H); **LCMS**: m/z 288.06(M⁺, 99.08),
131 290.06 (M+2, 33.0).

132 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(2''-methoxyphenyl)prop-2-ene-1-one (**3l**): Yellow color solid,
133 Yield: 85%. Recrystallized from chloroform. **FT-IR** (KBr ν_{\max} cm⁻¹): 778 (C-Cl), 1681 (str, CH=CH
134 conjugated), 1782 (intense conjugated C=O band), 2831 (-OCH₃), 3516 (Ar -OH); ¹H NMR (CDCl₃
135 400 MHz) δ (ppm): 2.41 (Ar-OCH₃), 7.78 (d, 1H, H _{β} , $J = 16.3$ Hz), 7.89 (d, 1H, H _{α} , $J = 16.2$ Hz), 6.61-
136 8.17 (m, 7H, Ar- H), 12.39 (s, Ar-OH); **LC-MS**: m/z 288.06 (M⁺, 99.05), 290.06 (M+2, 33.04).
137 (literature (32)).

138 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(pyridin-4''-yl)prop-2-ene-1-one (**3m**), cream color solid,
139 yeild 95%. Recrystallized from ethanol. m.p: 150°C; **FT- IR** (KBr ν_{\max} cm⁻¹), 775 (C-Cl), 1258 (str,
140 C=N conjugated), 1684 (str,CH=CH conjugated), 1787 (intense conjugated C=O band), 3221 (Ar
141 C-OH); ¹H NMR (CDCl₃ 400MHz) δ (ppm): 6.09 (s, Ar-OH), 6.96 (d, 1H, H _{α} , $J=16$ Hz), 8.06 (d,
142 1H, H _{β} , $J=16.8$ Hz), 7.08-8.84 (m, 7H, Ar- H); **LCMS**: m/z 259.69 (M⁺, 99.06), 261.69 (M+2, 33.02).

143 (*E*)-1-(5'-Chloro-2'-hydroxyphenyl)-3-(thiophen-2''-yl)prop-2-ene-1-one (**3n**): Yellow color solid;
144 Yield: 95%. Recrystallized from ethanol. **FT-IR** (KBr ν_{\max} cm⁻¹): 856 (C-S), 771 (C-Cl), 1688 (str,


145 CH=CH conjugated), 1779 (intense conjugated C=O band), 3228 (Ar-OH); ¹H NMR (CDCl₃ 400
146 MHz) δ (ppm): 7.38 (d, 1H, H_α, J = 16.3 Hz), 7.59 (d, 1H, H_β, J = 16.0 Hz), 6.94-8.32 (m, 6H, Ar H),
147 12.46 (s, Ar-OH); LC-MS: m/z 264.72 (M⁺, 99.09), 266.72 (M⁺, 33.07). (literature (33)).

148

149 (E)-(1-(5'-Chloro-2'-hydroxyphenyl)-3-(furan-2''-yl)prop-2-ene-1-one (**3o**), yellow color solid, yield
150 95%. Recrystallized from ethanol. m.p: 190^oC; FT-IR (KBr ν_{max}cm⁻¹), 744 (furon) , 775 (C-Cl), 1685
151 (str, CH=CH conjugated), 1776 (intense conjugated C=O band), 3230 (Ar -OH); ¹HNMR (CDCl₃
152 400MHz) δ (ppm): 6.98 (s, Ar-OH), 7.34 (d, 1H, H_α, J=16.0Hz), 7.54 (d, 1H, H_β, J=16.5Hz), 6.87-
153 8.17 (m, 7H, Ar H); LCMS: m/z 248.66 (M⁺, 99.03), 250.66(M⁺, 33.01).

154

155



Scheme 1. Synthesis of chalcones (3a-3o). Reagents and conditions: (a) ethanol, KOH, and room temperature; (1) 5-chloro-2-hydroxyacetophenone; R''-CHO aryl or heteroaryl aldehydes. R'' = ring B; 3a: 2''-fluorophenyl; 3b: 3''-fluorophenyl; 3c: 4''-fluorophenyl; 3d: 2''-chlorophenyl; 3e: 3''-chlorophenyl; 3f: 4''-chlorophenyl; 3g: 2''-methoxyphenyl; 3h: 3''-methoxyphenyl; 3i: 4''-methoxyphenyl; 3j: 2''-hydroxyphenyl; 3k: 3''-hydroxyphenyl; 3l: 4''-hydroxyphenyl; 3m: 4''-pyridinyl; 3n: 2''-thienyl; 3o: 2''-furfuryl.

156

157

158 **Antibacterial evaluation:** Antibacterial activity was evaluated against four clinically
159 significant bacterial strains, including the Gram-positive *Staphylococcus aureus*, *Bacillus*
160 *subtilis*, and the Gram-negative *Escherichia coli* and *Proteus vulgaris*. Benzyl penicillin was
161 used as the reference standard by following the previously reported technique [34]. The glass
162 ware was sterilized at 160 °C for 2 hours in a hot air oven. The medium was sterilized, and
163 then standard drug solutions (benzyl penicillin) as well as the target compounds (**3a-3o**) were
164 prepared. In the meantime, a nutritional agar medium was prepared (composition: peptone
165 0.5 percent, meat extract 0.3 percent, sodium chloride 0.5 percent, agar 2 percent, distilled
166 water to make up to 100 mL, and pH was adjusted to a value of 7.2). In 1000 mL of distilled
167 water add measure amount of peptone, meat extract, and sodium chloride were dissolved to
168 maintain pH of 7.2. As soon as the agar was dissolved, the medium was transferred into 25
169 mL conical flasks and placed in the refrigerator. The nutrient medium used in the study was
170 sterilized using an autoclave at 121°C and 15 lbs/sq. inch pressure. Sterilization of the petri
171 plates, test tubes, pipettes, and borers required for the experiment was accomplished using
172 dry heat sterilization using a hot air oven. Cultures of the various organisms (18 hours old)
173 were collected, and sterile water was used to form a suspension of the microorganisms in
174 order to test their viability. This solution was used as an inoculum later on the amount of
175 bacteria present in each sample was determined using the pour plate method. It was necessary
176 to place the inoculated agar media in sterile petri dishes with a diameter of 10 cm and allow it
177 to solidify before continuing. In DMSO, solutions of test substances at concentrations of
178 0.1 μg/mL were generated. Borer in the suitable media was utilized to manufacture the 5 mm
179 diameter cups. Five wells were formed on each plate. Three wells were used for testing


180 substances: one for standard compounds, one for control compounds, and one for a
 181 combination of both. It was necessary to place sample into each well before placing the plates
 182 in the refrigerated for 45 minutes to allow diffusion to take place. After an 18-hour incubation
 183 period at 37°C, the plates were examined for the presence of inhibitory zones. In order to
 184 decrease the possibility of experimental errors, the experiments were carried out in triplicate
 185 on the same day and under the same conditions. In order to determine the values of the zone
 186 of inhibition, a vernier was used, and the results were presented as a mean of three values
 187 with standard deviation.

188 Results and discussions

189 **Chemistry:** Chalcones were produced by the Claisen-Schmidt condensation of 5'-chloro-2'-
 190 hydroxy acetophenone with substituted aryl aldehydes and unsubstituted heteroaryl
 191 aldehydes, which were then purified (3a-3o). Recrystallization was used to purify all of the
 192 compounds, with either ethanol or chloroform being used as the recrystallizing solvent to
 193 achieve maximum purity. The structures of the compounds were investigated by using FT-IR,
 194 ¹H NMR, and mass spectroscopy techniques, among others. Two characteristic absorption
 195 bands with wave numbers of 1610-1685 cm⁻¹ and 1704-1787 cm⁻¹ respectively,
 196 corresponding to -C=C- and -C=O, respectively were seen in their FT-IR spectrum. On the
 197 other hand, the vinylic protons (H and H) of chalcones revealed two distinct doublet peaks in
 198 their ¹H NMR spectra, with chemical shift values of 6.96-7.95 and 7.09-8.06 ppm,
 199 respectively. Multiple peaks were observed for the other aromatic protons, with chemical
 200 shift values ranging from 6.72 to 8.06 ppm, while a singlet peak was observed for the -OH
 201 proton, with a chemical shift value of more than 12 ppm. M⁺ peaks were found in the mass
 202 spectra of all the compounds, which matched to their molecular weights, as well as an
 203 isotopic M+2 peak, which corresponded to the chlorine isotope (³⁷Cl) atom present in these
 204 molecules.

205 **Evaluating antibacterial activity:** The antibacterial activity of all the synthesized
 206 compounds was tested against four bacterial species, including the Gram-positive
 207 *Staphylococcus aureus* and *Bacillus subtilis* and the Gram-negative, *Escherichia coli* and
 208 *Proteus vulgaris*, respectively. The results indicate that 2'-hydroxy-5'-chlorophenyl chalcones
 209 possess considerable antibacterial activity. The nature of ring-B, on the other hand, is critical
 210 for the intensity of the activity (Table 2).

211 Table 2. Antibacterial and antifungal activity results of compounds **3a-3o** (Mean±SD)*



212

Entry	R	Microorganisms			
		<i>S.aureus</i>	<i>B.subtilis</i>	<i>E.coli</i>	<i>P.vulgaris</i>
3a	2-fluorophenyl	21.56±0.45	22.83±0.61	12.45±0.34	16.30±0.29
3b	3-fluorophenyl	20.13±0.29	23.02±0.19	11.02±0.39	15.43±0.61
3c	4-fluorophenyl	22.03±0.24	21.02±0.34	12.32±0.43	14.78±0.65

3d	2-chlorophenyl	17.87±0.54	19.22±0.31	11.56±0.90	12.32±0.43
3e	3-chlorophenyl	20.12±0.67	23.22±0.89	11.67±0.33	14.23±0.19
3f	4-chlorophenyl	19.54±0.32	23.87±0.12	12.33±0.57	15.22±0.43
3g	2-methoxyphenyl	18.14±0.54	18.19±0.23	10.14±0.75	12.43±0.76
3h	3-methoxyphenyl	19.55±0.65	18.06±0.22	11.54±0.12	13.53±0.21
3i	4-methoxyphenyl	19.12±0.42	19.16±0.54	11.14±0.16	12.55±0.65
3j	2-hydroxyphenyl	23.11±0.34	24.12±0.18	14.65±0.76	20.54±0.76
3k	3-hydroxyphenyl	20.32±0.55	21.51±0.23	13.93±0.65	18.19±0.43
3l	4-hydroxyphenyl	23.14±0.18	22.11±0.73	14.12±0.92	19.55±0.32
3m	3-pyridinyl	27.52±0.16	28.85±0.11	22.05±0.16	23.18±0.17
3n	2-thienyl	26.56±0.21	27.09±0.22	21.14±0.21	22.14±0.12
3o	2-furyl	26.12±0.52	27.05±0.19	18.12±0.52	19.67±0.19
Benzyl penicillin	-	24.06±0.05	27.02±0.02	14.05±0.05	19.04±0.03

*Results are mean of three experiments±Standard Deviation

213
214

215 We found that just three of the chalcones examined had potential antibacterial action against
216 all the bacterial strains tested: **3m**, **3n**, and **3o**, which all had the heteroaryl ring as a ring-B
217 component. The activity of these compounds exceeds that of the ordinary benzyl penicillin by
218 a significant margin. The bioisosteric pyridinyl scaffold in compound **3m** demonstrated the
219 greatest activity, with an inhibitory zone (in mm) of 27.52±0.16, 28.85±0.11, 22.05±0.16, and
220 23.18±0.17 against *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli*, and *Proteus*
221 *vulgaris*, respectively, among the compounds tested. In a similar way, the compounds **3n** and
222 **3o**, which included thienyl and furyl moieties, that shown approximately equivalent activity
223 against *Staphylococcus aureus* and *Bacillus subtilis*, respectively. To the contrary, **3n** was
224 more effective than **3o** against *Escherichia coli* and *Proteus vulgaris*, with zone of inhibition
225 values of 21.14±0.21 and 22.14±0.12 for each pathogen, respectively. This could be owing to
226 the presence of a sulfur atom within the thienyl ring. Antibacterial activity of the compounds
227 **3j** and **3l**, which contain the electron-releasing -OH group at the ortho and para-positions of
228 the phenyl rings at the ring-B portion, was moderate against all the tested bacterial species,
229 with zone of inhibition values that were comparable to those of benzyl penicillin in all cases.
230 The rest of the compounds, which contained electron-releasing methoxy groups as well as
231 halogen atoms, exhibited only moderate activity. The findings reveal that chalcones with
232 heteroaryl rings are more effective in inhibiting bacterial growth than standard chalcones with
233 two phenyl rings connected to the ketovinyl component of chalcones in terms of antibacterial
234 activity. The structures of the most potent compounds were represented in figure 2.

235




Figure 2. Structures of the most potent antibacterial chalcones **3m**, **3n** and **3o**

239
240

Conclusion

241 We have synthesized and tested the antibacterial activity of fifteen chalcones bearing chlorine
242 and hydroxyl groups on the ring-A moiety. All of the compounds were purified and
243 characterized. It was discovered that the compounds possessing a heteroaryl scaffold at the
244 ring-B region of chalcones had good antibacterial activity against all of the strains tested,
245 with activity greater than that of the standard benzyl penicillin. The most potent antibacterial
246 compounds **3m**, **3n**, and **3o**, can be considered as potential lead compounds for the design
247 and development of improved antibacterial agents. As part of our ongoing research, we are
248 testing these compounds against methicillin-resistant *Staphylococcus aureus* (MRSA) strains
249 to determine their probable mode of action for the proposed activity.

Ethical Approval:

251 As per international standard or university standard ethical approval has been collected and
252 preserved by the authors.

253

254

COMPETING INTERESTS DISCLAIMER:

256

257 Authors have declared that no competing interests exist. The products used for this research
258 are commonly and predominantly use products in our area of research and country. There is
259 absolutely no conflict of interest between the authors and producers of the products because
260 we do not intend to use these products as an avenue for any litigation but for the advancement
261 of knowledge. Also, the research was not funded by the producing company rather it was
262 funded by personal efforts of the authors.

263

264

265

References

- 267 1. Weder A.shiva. Biological and structure activity evaluation of chalcone derivatives
268 against bacteria and fungi. J Braze Chem Soc.2013;24(1):133-144.
- 269 2. Yazdan SK, Sagar GV, Shaik AB. Biological and synthetic potentiality of chalcones.
270 J Chem Pharm Res. 2015;7(11):829-42.
- 271 3. Yao LH, Jiang YM, Shi J, Tomas-Barberan FA, Datta N, Singanusong R, Chen SS.
272 Flavonoids in food and their health benefits. Plant foods for human nutrition. 2004
273 Jul;59(3):113-22.

- 274 4. Rocha S, Ribeiro D, Fernandes E, Freitas M. A systematic review on anti-diabetic
275 properties of chalcones. *Current medicinal chemistry*. 2020 Apr 1;27(14):2257-321.
- 276 5. Jae-Chul-Jung, Yngnam Lee, Donguk min, mankil jung. Practical synthesis of chalcone
277 derivatives and their biological activities. *Molecules*. 2017;22:1872.
- 278 6. Faeghen Farhadi, Bahman Khameneh, Menhrdad Iranshahi, Milad Iranshahi.
279 Antibacterial activities of flavonoids and their structural activity
280 relationship. *phytotherapy research*. 2019;33:13-40.
- 281 7. Shaik A, Bhandare RR, Palleapati K, Nissankararao S, Kancharlapalli V, Shaik S.
282 Antimicrobial, antioxidant, and anticancer activities of some novel isoxazole ring
283 containing chalcone and dihydropyrazole derivatives. *Molecules*. 2020
284 Jan;25(5):1047.
- 285 8. Dan W, Dai J. Recent developments of chalcones as potential antibacterial agents in
286 medicinal chemistry. *European journal of medicinal chemistry*. 2020 Feb
287 1;187:111980.
- 288 9. Lokesh BV, Prasad YR, Shaik AB. Synthesis and biological activity of novel 2, 5-
289 dichloro-3-acetylthiophene chalcone derivatives. *Ind. J. Pharm. Educ. Res.* 2017 Oct
290 1;51:679-90.
- 291 10. Rani M, Yusuf M, Khan SA. Synthesis and in-vitro-antibacterial activity of [5-(furan-
292 2-yl)-phenyl]-4, 5-carbothioamide-pyrazolines. *Journal of Saudi Chemical Society*.
293 2012 Oct 1;16(4):431-6.
- 294 11. Rammohan A, Reddy JS, Sravya G, Rao CN, Zyryanov GV. Chalcone synthesis,
295 properties and medicinal applications: a review. *Environmental Chemistry Letters*.
296 2020 Mar;18(2):433-58.
- 297 12. Jasim HA, Nahar L, Jasim MA, Moore SA, Ritchie KJ, Sarker SD. Chalcones:
298 Synthetic Chemistry Follows Where Nature Leads. *Biomolecules*. 2021
299 Aug;11(8):1203.
- 300 13. Emam SH, Sonousi A, Osman EO, Hwang D, Kim GD, Hassan RA. Design and
301 synthesis of methoxyphenyl-and coumarin-based chalcone derivatives as anti-
302 inflammatory agents by inhibition of NO production and down-regulation of NF- κ B
303 in LPS-induced RAW264. 7 macrophage cells. *Bioorganic Chemistry*. 2021 Feb
304 1;107:104630.
- 305 14. Salehi B, Quispe C, Chamkhi I, El Omari N, Balahbib A, Sharifi-Rad J, Bouyahya A,
306 Akram M, Iqbal M, Docea AO, Caruntu C. Pharmacological Properties of Chalcones:
307 A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence.
308 *Frontiers in Pharmacology*. 2021 Jan 18;11:2068.
- 309 15. Shaik AB, Prasad YR, Shahanaaz S. Design, facile synthesis, characterization and
310 computational evaluation of novel isobutylchalcones as cytotoxic agents: part-A.
311 *FABAD J. Pharm. Sci.* 2015;40:7-22.
- 312 16. Spatafora C, Tringali C. Natural-derived polyphenols as potential anticancer agents.
313 *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-
314 Anti-Cancer Agents)*. 2012 Oct 1;12(8):902-18.
- 315 17. Dandawate P, Ahmed K, Padhye S, Ahmad A, Biersack B. Anticancer Active
316 heterocyclic chalcones: recent developments. *Anti-Cancer Agents in Medicinal*

- 317 Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2021 Mar
318 1;21(5):558-66.
- 319 18. Shaik AB, Bhandare RR, Nissankararao S, Edis Z, Tangirala NR, Shahanaaz S,
320 Rahman MM. Design, facile synthesis and characterization of dichloro substituted
321 chalcones and dihydropyrazole derivatives for their antifungal, antitubercular and
322 antiproliferative activities. *Molecules*. 2020 Jan;25(14):3188.
- 323 19. Konidala SK, Kotra V, Danduga RC, Kola PK, Bhandare RR, Shaik AB. Design,
324 multistep synthesis and in-vitro antimicrobial and antioxidant screening of coumarin
325 clubbed chalcone hybrids through molecular hybridization approach. *Arabian Journal*
326 *of Chemistry*. 2021 Jun 1;14(6):103154.
- 327 20. Kasetti AB, Singhvi I, Nagasuri R, Bhandare RR, Shaik AB. Thiazole-Chalcone
328 Hybrids as Prospective Antitubercular and Antiproliferative Agents: Design,
329 Synthesis, Biological, Molecular Docking Studies and In Silico ADME Evaluation.
330 *Molecules*. 2021 Jan;26(10):2847.
- 331 21. Osipova VP, Polovinkina MA, Telekova LR, Velikorodov AV, Stepkina NN,
332 Berberova NT. Synthesis and antioxidant activity of new hydroxy derivatives of
333 chalcones. *Russian Chemical Bulletin*. 2020 Mar;69(3):504-9.
- 334 22. Dev S, Thomas Parambi DG, Baby B, Mathew GE, Omnia Magdy H, Joy M, Sudev
335 S, Mathew B. An environment-friendly synthesis of piperonal chalcones and their
336 cytotoxic and antioxidant evaluation. *Letters in Drug Design & Discovery*. 2020 Feb
337 1;17(2):138-44.
- 338 23. Tantawy MA, Sroor FM, Mohamed MF, El-Naggar ME, Saleh FM, Hassaneen HM,
339 Abdelhamid IA. Molecular docking study, cytotoxicity, cell cycle arrest and apoptotic
340 induction of novel chalcones incorporating thiadiazolyl isoquinoline in cervical
341 cancer. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal*
342 *Chemistry-Anti-Cancer Agents)*. 2020 Jan 1;20(1):70-83.
- 343 24. Mellado Garcia M, Reyna M, Weinstein-oppenheimer C. Preliminary evaluation of
344 cytotoxicity for small chalcones on breast and colorectal cancer cell line: synthesis and
345 structure activity relationship. *Journal of Pharmacology and Therapeutic Forecast*.
346 2018;1:1-5.
- 347 25. Qin HL, Zhang ZW, Lekkala R, Alsulami H, Rakesh KP. Chalcone hybrids as
348 privileged scaffolds in antimalarial drug discovery: a key review. *European journal of*
349 *medicinal chemistry*. 2020 May 1;193:112215.
- 350 26. Cheng-ying hseieh, Pi-wen ko, yo-jui chang. Design and synthesis of benzimidazole
351 chalcone derivatives as potential anticancer agents. *Molecules*. 2019;24:3259
- 352
- 353 27. Syahri J, Nasution H, Nurohmah BA, Purwono B, Yuanita E. Aminoalkylated
354 chalcone: synthesis, biological evaluation, and docking simulation as potent
355 antimalarial agents. *J Appl Pharm Sci*. 2020;10(06):001-5.
- 356 28. Sawant, Arun & Nirwan, R.. (2013). SYNTHESIS AND ANTIBACTERIAL
357 ACTIVITY OF SOME 1,5-BENZOTHAZEPINES. *Indian Journal of Heterocyclic*
358 *Chemistry*. 23. 51-54.

- 359 29. Hasan A, Khan KM, Sher M, Maharvi GM, Nawaz SA, Choudhary MI, Atta-ur-
360 Rahman, Supuran CT. *Journal of enzyme inhibition and medicinal chemistry*. 2005
361 Feb 1;20(1):41-7.
- 362 30. Jung SH, Park SY, Kim-Pak Y, Lee HK, Park KS, Shin KH, Ohuchi K, Shin HK,
363 Keum SR, Lim SS. Synthesis and PPAR- γ ligand-binding activity of the new series of
364 2'-hydroxychalcone and thiazolidinedione derivatives. *Chemical and pharmaceutical*
365 *bulletin*. 2006;54(3):368-71.
- 366 31. Saito Y, Mizokami A, Tsurimoto H, Izumi K, Goto M, Nakagawa-Goto K. 5'-Chloro-
367 2, 2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
368 *European journal of medicinal chemistry*. 2018 Sep 5;157:1143-52. (FOR
369 Compounds **9 and 10**).
- 370 32. De Meyer N, Haemers A, Mishra L, Pandey HK, Pieters LA, Vanden Berghe DA,
371 Vlietinck AJ. 4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
372 *Journal of medicinal chemistry*. 1991 Feb;34(2):736-46.
- 373 33. Gupta S, Dhawan S. Photochemistry of chromones: photoreorganisation of 3-alkoxy-
374 2-thienyl-4-oxo-4 H-1-benzopyrans. *Journal of the Chemical Society, Perkin*
375 *Transactions 1*. 1999(16):2391-5.
- 376 34. Lagu SB, Yejella RP, Bhandare RR, Shaik AB. Design, synthesis, and antibacterial
377 and antifungal activities of novel trifluoromethyl and trifluoromethoxy substituted
378 chalcone derivatives. *Pharmaceuticals*. 2020 Nov;13(11):375.

379

380

381